<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2890">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390555</url>
  </required_header>
  <id_info>
    <org_study_id>PCHF-COVICAV</org_study_id>
    <nct_id>NCT04390555</nct_id>
  </id_info>
  <brief_title>The Global PCHF-COVICAV Registry</brief_title>
  <acronym>PCHF-COVICAV</acronym>
  <official_title>COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has
      never seen before and is overwhelming the capacities of healthcare systems worldwide.
      Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk
      factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are
      more and more reports of cardiac manifestations with the viral disease.

      Aim: The purpose of the study is to characterise the clinical course of adult inpatients with
      COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry.

      Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected
      laboratory, electrocardiography and echocardiography parameters, treatment and outcome will
      be collected. The principal investigator provides dedicated electronic case report form. The
      primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay,
      hospital length of stay, the need and duration of invasive mechanical ventilation,
      cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and
      cardiovascular mortality after 3 and 6 months from index hospitalisation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>In-hospital mortality.</measure>
    <time_frame>Hospitalization period, assessed up to 30 days</time_frame>
    <description>All-cause and cardiovascular mortality during index hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The length of stay in the intensive care unit.</measure>
    <time_frame>Hospitalization period in the ICU, assessed up to 30 days</time_frame>
    <description>The duration of hospitalization on the intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of hospitalization.</measure>
    <time_frame>Hospitalization period, assessed up to 30 days</time_frame>
    <description>The total length of stay in the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need and duration of invasive mechanical ventilation.</measure>
    <time_frame>Hospitalization period, assessed up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>COVID-19</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CV involvement</arm_group_label>
    <description>Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with COVID-19 without preexisting cardiac involvement.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult inpatients (≥18 years old) with laboratory-confirmed COVID-19. Subjects with
        pre-existing cardiovascular disease and/or cardiac manifestations of COVID-19 infection
        (heart failure, acute coronary syndrome, myocarditis, arrhythmias, sudden cardiac arrest)
        and/or cardiovascular risk factors (dyslipidemia, hypertension, diabetes) are the focus of
        the study. Hospitalised subjects with COVID-19, but without cardiovascular disease or risk
        factors, will be used as a control population.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult inpatients (≥18 years old) with laboratory-confirmed COVID-19.

        Exclusion Criteria:

          -  Age &lt;18 years old.

          -  Outpatients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, Prof. Dr. med</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Zurich, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Flammer, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mateusz Sokolski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wroclaw Medical University, Wroclaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mateusz Sokolski, MD, PhD</last_name>
    <phone>+48717331112</phone>
    <email>mateusz.sokolski@umed.wroc.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sander Trenson, MD</last_name>
    <phone>+41442554939</phone>
    <email>sander.trenson@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zurich Heart Center, Unispital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3. Erratum in: Intensive Care Med. 2020 Apr 6;:.</citation>
    <PMID>32125452</PMID>
  </reference>
  <reference>
    <citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.</citation>
    <PMID>32211816</PMID>
  </reference>
  <reference>
    <citation>Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1. Retraction in: N Engl J Med. 2020 Jun 4;:.</citation>
    <PMID>32356626</PMID>
  </reference>
  <reference>
    <citation>Cunningham JW, Ferreira JP, Deng H, Anker SD, Byra WM, Cleland JGF, Gheorghiade M, Lam CSP, La Police D, Mehra MR, Neaton JD, Spiro TE, van Veldhuisen DJ, Greenberg B, Zannad F. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. JACC Heart Fail. 2020 May;8(5):359-368. doi: 10.1016/j.jchf.2019.12.009. Epub 2020 Mar 11.</citation>
    <PMID>32171760</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.</citation>
    <PMID>32219356</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link? JACC Heart Fail. 2020 Jun;8(6):512-514. doi: 10.1016/j.jchf.2020.03.004. Epub 2020 Apr 10.</citation>
    <PMID>32360242</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.</citation>
    <PMID>32325026</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Cardiovascular Risk Factor</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

